ArticleGene therapy2002
Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides.
Article in Gene therapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 97 citations in OpenAlex.
- In situ cellular hitchhiking of nanoparticles for drug delivery.Advanced drug delivery reviews · 2024Review
- Compatibility of Nucleobases Containing Pt(II) Complexes with Red Blood Cells for Possible Drug Delivery Applications.Molecules (Basel, Switzerland) · 2023Article
- RBC-Derived Optical Nanoparticles Remain Stable After a Freeze-Thaw Cycle.Langmuir : the ACS journal of surfaces and colloids · 2020Article
- Clickable Methyltetrazine-Indocarbocyanine Lipids: A Multicolor Tool Kit for Efficient Modifications of Cell Membranes.Bioconjugate chemistry · 2019Article
- Red Blood Cell-Facilitated Photodynamic Therapy for Cancer Treatment.Advanced functional materials · 2016Article
- Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells.Frontiers in pharmacology · 2016Review
- Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities.Therapeutic delivery · 2016Review
- Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.Therapeutic delivery · 2015Review
- Targeted thrombolysis strategies for neuroprotective effect.Neural regeneration research · 2014Article
- Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2014Article
- Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Drug-loaded sickle cells programmed ex vivo for delayed hemolysis target hypoxic tumor microvessels and augment tumor drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Encapsulation of FITC to monitor extracellular pH: a step towards the development of red blood cells as circulating blood analyte biosensors.Biomedical optics express · 2011Article
- Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.PloS one · 2011Article
- Drug delivery by red blood cells: vascular carriers designed by mother nature.Expert opinion on drug delivery · 2010Review
- Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.Journal of controlled release : official journal of the Controlled Release Society · 2009Article
- Biological gene delivery vehicles: beyond viral vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Review
- In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes.Peptides · 2007Article
- Article
- Erythrocyte ghost-mediated gene delivery for prolonged and blood-targeted expression.Gene therapy · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An important determinant for the success of every new therapy is the ability to deliver the molecules of interest to the target cells or organ. This selective delivery is even more complex when the therapeutic agents are peptides, modified oligonucleotides or genes. In this paper we summarize the possibility of using autologous erythrocytes for the delivery and targeting of new and conventional therapeutics. In fact, a number of macromolecules can be encapsulated by different procedures into human erythrocytes. These modified cells can then be re-infused into the same or a compatible recipient where they can circulate for several weeks. However, drug-loaded erythrocytes can also be modified to be selectively recognized by tissue macrophages. These phagocyte cells recognize the modified drug-loaded erythrocytes which are able to release their content into the macrophage. The feasibility and safety of the use of erythrocytes as drug delivery systems was evaluated in 10 cystic fibrosis patients, where a sustained release of corticosteroids from dexamethasone 21-phosphate-loaded erythrocytes was obtained. In vitro human erythrocytes were found to be able to deliver ubiquitin analogues and modified oligonucleotides to macrophages. Thus, drug-loaded erythrocytes are safe and useful carriers of new and conventional therapeutics and can be advantageous delivery systems for new clinical applications where proteins and oligonucleotides are therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.